Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Gene Therapy Guidances From US FDA Coming In About 6 Weeks, Gottlieb Says

Executive Summary

Potential accelerated approval endpoints will be addressed; FDA Commissioner expects gene therapy to become a 'backbone' treatment as antibodies are now.

You may also be interested in...



Gene Therapy Oversight To Be Streamlined By US FDA, NIH

Streamlining adverse event reports among reform ideas; NIH's Recombinant DNA Advisory Committee likely to drop review of more routine protocols.

Gene Therapies Need Long-Term Follow-Up Plan From Outset Or Risk Clinical Hold

Although a sponsor may conclude that a long-term follow-up protocol is not necessary for a gene therapy, FDA may have a different interpretation, and the agency won't let studies start if that's the case, draft gudiance states.

Gene Therapy 'Cassettes' Could Speed, Cheapen Manufacturing, Gottlieb Says

US FDA Commissioner teases endpoints, suggests accelerated approval plan and post-marketing considerations for gene therapies targeting hemophilia.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

MT142313

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel